nach oben

Erschienen in:

01.07.2014

The Long Elusive IgM Fc Receptor, FcμR

verfasst von: Hiromi Kubagawa, Satoshi Oka, Yoshiki Kubagawa, Ikuko Torii, Eiji Takayama, Dong-Won Kang, Dewitt Jones, Naonori Nishida, Toshio Miyawaki, Luigi F. Bertoli, Sheila K. Sanders, Kazuhito Honjo

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

IgM exists as both a monomer on the surface of B cells and a pentamer secreted by plasma cells. Both pre-immune “natural” and antigen-induced “immune” IgM antibodies are important for protective immunity and for immune regulation of autoimmune processes by recognizing pathogens and self-antigens. Effector proteins interacting with the Fc portion of IgM, such as complement and complement receptors, have thus far been proposed but fail to fully account for the IgM-mediated protection and regulation. A major reason for this deficit in our understanding of IgM function seems to be lack of data on a long elusive Fc receptor for IgM (FcμR). We have recently identified a bona fide FcμR in both humans and mice. In this article we briefly review what we have learned so far about FcμR.

Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol. 1991;9:457–92.PubMedCrossRef

Daëron M. Fc receptor biology. Annu Rev Immunol. 1997;15:203–34.PubMedCrossRef

Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol. 2003;21:177–204.PubMedCrossRef

Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005;23(1):41–51.PubMedCrossRef

Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. J Exp Med. 2009;206(12):2779–93.PubMedCentralPubMedCrossRef

Honjo K, Kubagawa Y, Jones DM, Dizon B, Zhu Z, Ohno H, et al. Altered Ig levels and antibody responses in mice deficient for the Fc receptor for IgM (FcμR). Proc Natl Acad Sci U S A. 2012;109(39):15882–7.PubMedCentralPubMedCrossRef

Moretta L, Webb SR, Grossi CE, Lydyard PM, Cooper MD. Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM (Tμ) or IgG (Tγ). J Exp Med. 1977;146(1):184–200.PubMedCrossRef

Reinherz EL, Moretta L, Roper M, Breard JM, Mingari MC, Cooper MD, et al. Human T lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies: a comparison. J Exp Med. 1980;151(4):969–74.PubMedCrossRef

Sanders SK, Kubagawa H, Suzuki T, Butler JL, Cooper MD. IgM binding protein expressed by activated B cells. J Immunol. 1987;139(1):188–93.PubMed

10.

Ohno T, Kubagawa H, Sanders SK, Cooper MD. Biochemical nature of an Fcμ receptor on human B-lineage cells. J Exp Med. 1990;172(4):1165–75.PubMedCrossRef

11.

Nakamura T, Kubagawa H, Ohno T, Cooper MD. Characterization of an IgM Fc-binding receptor on human T cells. J Immunol. 1993;151(12):6933–41.PubMed

12.

Vire B, David A, Wiestner A. TOSO, the Fcμ receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation. J Immunol. 2011;187(8):4040–50.PubMedCentralPubMedCrossRef

13.

Pricop L, Rabinowich H, Morel PA, Sulica A, Whiteside TL, Herberman RB. Characterization of the Fcμ receptor on human natural killer cells. Interaction with its physiologic ligand, human normal IgM, specificity of binding, and functional effects. J Immunol. 1993;151(6):3018–29.PubMed

14.

Nguyen XH, Lang PA, Lang KS, Adam D, Fattakhova G, Foger N, et al. Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination. Blood. 2011;118(3):598–608.PubMedCrossRef

15.

Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity. 1998;8(4):461–71.PubMedCrossRef

16.

Honjo K, Kubagawa Y, Kubagawa H. Is Toso an antiapoptotic protein or an Fc receptor for IgM? Blood. 2012;119(7):1789–90.PubMedCrossRef

17.

Murakami Y, Narayanan S, Su S, Childs R, Krzewski K, Borrego F, et al. Toso, a functional IgM receptor, is regulated by IL-2 in T and NK cells. J Immunol. 2012;189(2):587–97.PubMedCentralPubMedCrossRef

18.

Hamburger AE, West Jr AP, Bjorkman PJ. Crystal structure of a polymeric immunoglobulin binding fragment of the human polymeric immunoglobulin receptor. Structure. 2004;12(11):1925–35.PubMedCrossRef

19.

Hoover RG, Dieckgraefe BK, Lynch RG. T cells with Fc receptors for IgA: induction of T alpha cells in vivo and in vitro by purified IgA. J Immunol. 1981;127(4):1560–3.PubMed

20.

Reljic R. In search of the elusive mouse macrophage Fcα receptor. Immunol Lett. 2006;107(1):80–1.PubMedCrossRef

21.

Maruoka T, Nagata T, Kasahara M. Identification of the rat IgA Fc receptor encoded in the leukocyte receptor complex. Immunogenetics. 2004;55(10):712–6.PubMedCrossRef

22.

Adachi T, Harumiya S, Takematsu H, Kozutsumi Y, Wabl M, Fujimoto M, et al. CD22 serves as a receptor for soluble IgM. Eur J Immunol. 2012;42(1):241–7.PubMedCrossRef

23.

Poe JC, Tedder TF. CD22 and Siglec-G in B cell function and tolerance. Trends Immunol. 2012;33(8):413–20.PubMedCentralPubMedCrossRef

24.

McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013;14(4):327–36.PubMedCentralPubMedCrossRef

25.

Randow F, MacMicking JD, James LC. Cellular self-defense: how cell-autonomous immunity protects against pathogens. Science. 2013;340(6133):701–6.PubMedCrossRef

26.

Tissot JD, Sanchez JC, Vuadens F, Scherl A, Schifferli JA, Hochstrasser DF, et al. IgM are associated to Sp alpha (CD5 antigen-like). Electrophoresis. 2002;23(7–8):1203–6.PubMedCrossRef

27.

Martinez VG, Moestrup SK, Holmskov U, Mollenhauer J, Lozano F. The conserved scavenger receptor cysteine-rich superfamily in therapy and diagnosis. Pharmacol Rev. 2011;63(4):967–1000.PubMedCrossRef

28.

Miyazaki T, Kurokawa J, Arai S. AIMing at metabolic syndrome. Towards the development of novel therapies for metabolic diseases via apoptosis inhibitor of macrophage (AIM). Circ J. 2011;75(11):2522–31.PubMedCrossRef

29.

Arai S, Maehara N, Iwamura Y, Honda S, Nakashima K, Kai T, et al. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep. 2013;3(4):1187–98.PubMedCrossRef

30.

Reth M. Antigen receptor tail clue. Nature. 1989;338(6214):383–4.PubMedCrossRef

31.

Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell. 1994;76(2):263–74.PubMedCrossRef

32.

Cambier JC. Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). J Immunol. 1995;155(7):3281–5.PubMed

33.

Vely F, Vivier E. Conservation of structural features reveals the existence of a large family of inhibitory cell surface receptors and noninhibitory/activatory counterparts. J Immunol. 1997;159(5):2075–7.PubMed

34.

Cambier JC. Inhibitory receptors abound? Proc Natl Acad Sci U S A. 1997;94(12):5993–5.PubMedCentralPubMedCrossRef

35.

Sidorenko SP, Clark EA. The dual-function CD150 receptor subfamily: the viral attraction. Nat Immunol. 2003;4(1):19–24.PubMedCrossRef

36.

Engels N, Konig LM, Heemann C, Lutz J, Tsubata T, Griep S, et al. Recruitment of the cytoplasmic adaptor Grb2 to surface IgG and IgE provides antigen receptor-intrinsic costimulation to class-switched B cells. Nat Immunol. 2009;10(9):1018–25.PubMedCrossRef

37.

Klein U, Tu Y, Stolovitzky GA, Keller JL, Haddad Jr J, Miljkovic V, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci U S A. 2003;100(5):2639–44.PubMedCentralPubMedCrossRef

38.

Riou C, Yassine-Diab B, van Grevenynghe J, Somogyi R, Greller LD, Gagnon D, et al. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med. 2007;204(1):79–91.PubMedCentralPubMedCrossRef

39.

Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–9.PubMedCentralPubMedCrossRef

40.

Shibuya A, Sakamoto N, Shimizu Y, Shibuya K, Osawa M, Hiroyama T, et al. Fcα/μ receptor mediates endocytosis of IgM-coated microbes. Nat Immunol. 2000;1(5):441–6.PubMedCrossRef

41.

Kikuno K, Kang DW, Tahara K, Torii I, Kubagawa HM, Ho KJ, et al. Unusual biochemical features and follicular dendritic cell expression of human Fcα/μ receptor. Eur J Immunol. 2007;37(12):3540–50.PubMedCrossRef

42.

Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O’Shea MA, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205(8):1797–805.PubMedCentralPubMedCrossRef

43.

Pichler WJ, Knapp W. Receptors for IgM-coated erythrocytes on chronic lymphatic leukemia cells. J Immunol. 1977;118(3):1010–5.PubMed

44.

Ferrarini M, Hoffman T, Fu SM, Winchester R, Kunkel HG. Receptors for IgM on certain human B lymphocytes. J Immunol. 1977;119(4):1525–9.PubMed

45.

Burns GF, Cawley JC, Barker CR. Characterization of the receptor for IgM present on human B lymphocytes. Immunology. 1979;36(3):569–77.PubMedCentralPubMed

46.

Rudders RA, Andersen J, Howard JP, Fried R. The binding of IgM to B lymphocytes. I. Studies of the binding of aggregated IgM to normal and leukemic human B lymphocytes. Clin Immunol Immunopathol. 1980;15(4):673–86.PubMedCrossRef

47.

Platsoucas CD, Kempin S, Karanas A, Clarkson B, Good RA, Gupta S. Receptors for immunoglobulin isotype on T and B lymphocytes from untreated patients with chronic lymphocytic leukaemia. Clin Exp Immunol. 1980;40(2):256–63.PubMedCentralPubMed

48.

Proto-Siqueira R, Panepucci RA, Careta FP, Lee A, Clear A, Morris K, et al. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood. 2008;112(2):394–7.PubMedCentralPubMedCrossRef

49.

Pallasch CP, Schulz A, Kutsch N, Schwamb J, Hagist S, Kashkar H, et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood. 2008;112(10):4213–9.PubMedCrossRef

50.

Pallasch CP, Wendtner CM. Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(3):498–501.PubMedCrossRef

51.

Li FJ, Kubagawa Y, McCollum MK, Wilson L, Motohashi T, Bertoli LF, et al. Enhanced levels of both membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia. Blood. 2011;118(18):4902–9.PubMedCentralPubMedCrossRef

52.

Duhren-von MM, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7415):309–12.CrossRef

53.

Stevenson FK, Hamblin TJ, Stevenson GT, Tutt AL. Extracellular idiotypic immunoglobulin arising from human leukemic B lymphocytes. J Exp Med. 1980;152(6):1484–96.PubMedCrossRef

54.

Qian GX, Fu SM, Solanki DL, Rai KR. Circulating monoclonal IgM proteins in B cell chronic lymphocytic leukemia: their identification, characterization and relationship to membrane IgM. J Immunol. 1984;133(6):3396–400.PubMed

55.

Bertoli LF, Kubagawa H, Borzillo GV, Mayumi M, Prchal JT, Kearney JF, et al. Analysis with antiidiotype antibody of a patient with chronic lymphocytic leukemia and a large cell lymphoma (Richter’s syndrome). Blood. 1987;70(1):45–50.PubMed

56.

Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804–15.PubMedCrossRef

57.

Lang KS, Lang PA, Meryk A, Pandyra AA, Boucher LM, Pozdeev VI, et al. Involvement of Toso in activation of monocytes, macrophages, and granulocytes. Proc Natl Acad Sci U S A. 2013;110(7):2593–8.PubMedCentralPubMedCrossRef

58.

Honjo K, Kubagawa Y, Kubagawa H. Is Toso/IgM Fc receptor (FcμR) expressed by innate immune cells? Proc Natl Acad Sci U S A. 2013;110(28):E2540–1.PubMedCentralPubMedCrossRef

59.

Ouchida R, Mori H, Hase K, Takatsu H, Kurosaki T, Tokuhisa T, et al. Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, and humoral immune responses. Proc Natl Acad Sci U S A. 2012;17:E2699–706.CrossRef

60.

Choi SC, Wang H, Tian L, Murakami Y, Shin DM, Borrego F, et al. Mouse IgM Fc receptor, FCMR, promotes B cell development and modulates antigen-driven immune responses. J Immunol. 2013;190(3):987–96.PubMedCentralPubMedCrossRef

61.

Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol. 2010;10(11):778–86.PubMedCrossRef

62.

Boes M, Esau C, Fischer MB, Schmidt T, Carroll M, Chen J. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J Immunol. 1998;160(10):4776–87.PubMed

63.

Ehrenstein MR, O’Keefe TL, Davies SL, Neuberger MS. Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response. Proc Natl Acad Sci U S A. 1998;95(17):10089–93.PubMedCentralPubMedCrossRef

64.

Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med. 1998;188(12):2381–6.PubMedCentralPubMedCrossRef

65.

Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA, Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med. 2000;192(2):271–80.PubMedCentralPubMedCrossRef

66.

Subramaniam KS, Datta K, Quintero E, Manix C, Marks MS, Pirofski LA. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J Immunol. 2010;184(10):5755–67.PubMedCentralPubMedCrossRef

67.

Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A. 2000;97(3):1184–9.PubMedCentralPubMedCrossRef

68.

Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med. 2000;191(7):1253–8.PubMedCentralPubMedCrossRef

Titel: The Long Elusive IgM Fc Receptor, FcμR
verfasst von: Hiromi Kubagawa
Satoshi Oka
Yoshiki Kubagawa
Ikuko Torii
Eiji Takayama
Dong-Won Kang
Dewitt Jones
Naonori Nishida
Toshio Miyawaki
Luigi F. Bertoli
Sheila K. Sanders
Kazuhito Honjo
Publikationsdatum: 01.07.2014
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe Sonderheft 1/2014
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-014-0022-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Long Elusive IgM Fc Receptor, FcμR

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2014

Treatment of Multifocal Motor Neuropathy with Intravenous Immunoglobulin

The Node of Ranvier in Multifocal Motor Neuropathy

Mechanistic Effects of IVIg in Neuroinflammatory Diseases: Conclusions Based on Clinicopathologic Correlations

Neuroinflammation in Alzheimer’s Disease: from Pathogenesis to a Therapeutic Target

Immunomodulation and AD – Down But Not Out

Natural IgM: Beneficial Autoantibodies for the Control of Inflammatory and Autoimmune Disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin